Abstract:Abstract 4475 Imatinib mesylate is a selective tyrosine kinase inhibitor targeting BCR-ABL fusion protein. In the therapy of either interferon refractory or newly diagnosed chronic myeloid leukemia (CML), imatinib significantly improved the prognosis of the disease, albeit with typically mild to moderate adverse effects. In recent years, increasing attention has been focused on the skin hypopigmentation developed after the initiation of imatinib therapy, especially in Asian countries such as India, with the incidence between 33% and 85%, though sparsely reported in western countries. The inhibition of c-kit by imatinib may be a possible explanation, but the exact mechanism for this hypopigmentation caused by imatinib and its potential risk in patients is poorly understood. Here we report our clinical observation of this side effect of imatinib therapy among Chinese CML patients in our institution, as well as a brief in vitro study aiming to investigate the mechanism of the hypopigmentory effect and evaluate its potential risk. Among 116 patients who took imatinib for CML therapy, 90 of them (77.6%) had reported to develop generalized hypopigmentation or whitening in the skin. This side effect usually developed within 3 months after initiation of imatinib, persistent during the therapy, and reversible upon imatinib discontinuation, according to our interviews and observation. More interestingly, in three of these CML patients who originally had vitiligo, the cosmetic appearance seemed to be improved during imatinib therapy due to the whitening effect on normal pigmented skin areas. To further confirm and understand this side effect, we examined the impact of imatinib on cultured normal human melanocytes derived from the foreskins of healthy Chinese adults. Melanocytes were treat with various concentrations of imatinib (1~16 μ M) for different periods of time (1~7 days). Cell proliferation and apoptosis were detected by cell counting kit-8 and flow cytometric assay, respectively. The melanogenic activity of the melanocytes was detected by melanin content assay and tyrosinase activity assay. Moreover, the role of stem cell factor (SCF) and its receptor c-kit in imatinib induced hypopigmentation were investigated. We found that imatinib not only concentration-dependently inhibited melanocyte proliferation in vitro (IC50=6.23 μ M), but also resulted in massive melanocyte apoptosis at concentrations higher than 8 μ M (P Disclosures: No relevant conflicts of interest to declare.

Optic disc edema as a possible complication of Imatinib mesylate (Gleevec)

Concurrence of imatinib-induced massive pleural/pericardial effusion and Campylobacter bacteremia in an adolescent with chronic myeloid leukemia

Case report: Pemigatinib-induced retinopathy: a serial examination of subretinal fluid secondary to an FGFR inhibitor

Tyrosine Kinase Inhibitor Imatinib Mesylate Induces Generalized Skin Hypopigmentation in Chinese Patients with Chronic Myelogenous Leukemia.

Disappearance of lentigines in a patient receiving imatinib treatment for familial gastrointestinal stromal tumor syndrome

[Concentration of gilteritinib in the cerebrospinal fluid of a patient with relapsed FLT3-ITD positive acute myeloid leukemia with optic nerve involvement]

Imatinib‑induced gynecomastia: A case report

Ocular Effects of MEK Inhibitor Therapy: Literature Review, Clinical Presentation, and Best Practices for Mitigation

Imatinib mesylate-induced acute hepatotoxicity

New features in MEK retinopathy

[The Impact of Glivec Related Side Effects on Daily Life in Chinese Patients with Chronic Myeloid Leukemia in the Chronic Phase].

Pembrolizumab-induced optic neuropathy - a case report

Imatinib@glycymicelles entrapped in hydrogel: preparation, characterization, and therapeutic effect on corneal alkali burn in mice

PEMBROLIZUMAB-RELATED BILATERAL OCULAR HYPOTONY ASSOCIATED WITH CILIARY DETACHMENTS AND MACULA OEDEMA: A TREATMENT-RESISTANT SIDE EFFECT

[Treatment of 54 Chronic Myelogenous Leukemia with Gleevec].

Imatinib Therapy of Chronic Myeloid Leukemia Significantly Reduces Carnitine Cell Intake, Resulting in Adverse Events

Imatinib mesylate-induced lichenoid drug eruption

Bilateral keratitis associated with afatinib therapy

Acute keratoconjunctivitis associated with tisotumab vedotin-tftv for metastatic cervical cancer

A Case Report of Imatinib-induced Acute Heart Failure and Literature Review

Optic Disc Infiltration as a Sign of Multiple Myeloma Recurrence